Comparative study between Ledipasvir based regimen and Daclatasvir based regimen as regard incidence of Hepatocellular Carcinoma after successful Therapy for patients with chronic hepatitis C virus infection

Abstract

CC is one of the most common malignancies worldwide and is ‎a major cause of death, because of its high frequency and poor ‎prognosis. It is especially common in Egypt, where ‎it develops on top of cirrhosis secondary to viral hepatitis C and ‎B. Since HCV infection is highly prevalent in Egypt, it ‎accounts to most of the cases of HCC in Egypt.‎ HCV infection is found in a variable proportion in HCC cases in different populations, accounting for 75-90% of cases in Japan, 31-47% in the U.S, 44-76% in Italy, and 60%-75% of HCC cases in Spain. Nowadays, treatment of HCV infection has shown a breakthrough. The standard interferon based therapy was replaced by the new oral direct antiviral agents. This revolutionized the outcome of treatment and complete viral eradication is now expected for most patients. Recently conflict has developed about rate of HCC occurrence after successful therapy using new DAA for patients with chronic HCV infection. The aim of this study was to compare between Ledipasvir based regimen and Daclatasvir based regimen as regard incidence of Hepatocellular Carcinoma after successful Therapy for patients with chronic hepatitis C virus infection.